CoChat

Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder

Open access
Goff, Donald C., Hill, Michele, Freudenreich, Oliver · 2010 · The Journal of Clinical Psychiatry
Cited by 135

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Article AbstractNonadherence with medication treatment is common but difficult to detect in patients with schizoaffective disorder and schizophrenia, almost half of whom take less than 70% of prescribed doses. Like patients in all areas of medicine, patients with schizoaffective disorder weigh the perceived benefits of medications against perceived disadvantages, but this process is complicated by their impaired insight, the stigma of the diagnosis, and the often troubling side effects of antipsychotic medication. Interventions to improve adherence include encouraging acceptance of the illness, drawing analogies with treatment for chronic medical disease, and involving the patient in decision making. Clinicians must remain nonjudgmental, encouraging patients to disclose problems with adherence and anticipating that improvement in adherence may require a prolonged effort. Selection of antipsychotic medication is critical to avoid adverse side effects, and some medications may provide a sense of well-being, such as improvement in insomnia, anxiety, or depression. Depot (rather than oral) antipsychotics can improve adherence and provide the clinician with reliable information about the dosage of medication received, which can be used for purposes of dose adjustments or to guide response to relapse. From the Schizophrenia Program, Harvard Medical School and Massachusetts General Hospital, Boston. This article was supported by an educational grant from Janssen, Division of Ortho-McNeill-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeill Janssen Scientific Affairs, LLC. Dr Goff is a consultant for Schering-Plough, Eli Lilly, F. Hoffman-La Roche, Takeda, Biovail, Solvay, and Dainippon Sumitomo; has received grant/research support from GlaxoSmithKline, Novartis, and Pfizer; and has received other financial support from Otsuka (Data Safety Monitoring Board). Dr Freudenreich is a consultant for Beacon Health Strategies, has received grant/research support from Pfizer, has received honoraria from Reed Medical Education, and has received other financial support from Lippincott Williams & Wilkins. Dr Hill has no personal affiliations or financial relationships with any commercial interest to disclose relative to this article. Corresponding author: Donald C. Goff, MD, Freedom Trail Clinic, 25 Staniford St, Boston, MA 02114 (goff@psych.mgh.harvard.edu).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.9096su1cc.04

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 135

Metadata

Authors
Goff, D. C., Hill, M., & Freudenreich, O.
Venue
The Journal of Clinical Psychiatry
Published
2010-12
Volume
71
Issue
suppl 2
Pages
20-26
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2027058533
Cited by
135
References
4
FWCI
9.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder. https://app.cochat.ai/papers/10.4088/jcp.9096su1cc.04
The paper
Goff, D. C., Hill, M., & Freudenreich, O. (2010). Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.9096su1cc.04

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.